Opticyte

Next-generation oximetry: allows clinicians real-time perfusion monitoring, improving patient outcomes and reducing healthcare costs in ICUs, ORs, and EDs.

  • Stage $1M in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Seattle, WA, US
  • Currency USD
  • Founded September 2016
  • Employees 4
  • Incorporation Type C-corp
  • Website Opticyte.com

Company Summary

The ‘Holy Grail’ of oximetry for critical care is to directly measure oxygen where it is actually used: inside cells. Opticyte is developing the CellSat™ 100, a novel cellular oximeter to address the significant unmet need of monitoring perfusion. Inadequate perfusion can lead to loss of limbs, multiple organ failure, and death. The Company’s new oximeter is poised to revolutionize patient monitoring in ICUs, ORs, and EDs.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free